Evidence map›Paper›PMID 29161281›Full record

ArticlePloS one2017

The administration of hydrogen sulphide prior to ischemic reperfusion has neuroprotective effects in an acute stroke model.

Chul-Woong Woo, Jae-Im Kwon, Kyung-Won Kim, Jeong-Kon Kim, Sang-Beom Jeon, Seung-Chae Jung, Choong-Gon Choi, Sang-Tae Kim, Jinil Kim, Su Jeong Ham and 5 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Black gas, bright future: HNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  2. Review
  3. Review
  4. The Slow-Releasing and Mitochondria-Targeted Hydrogen Sulfide (HInternational journal of molecular sciences · 2021
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Chul-Woong WooAsan Institute for Life Sciences, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Jae-Im KwonAsan Institute for Life Sciences, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Kyung-Won KimDepartment of Radiology, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Jeong-Kon KimDepartment of Radiology, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Sang-Beom JeonDepartment of Neurology, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Seung-Chae JungDepartment of Radiology, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Choong-Gon ChoiDepartment of Radiology, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Sang-Tae KimAsan Institute for Life Sciences, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Jinil KimAsan Institute for Life Sciences, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Su Jeong HamAsan Institute for Life Sciences, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Woo-Hyun ShimAsan Institute for Life Sciences, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Yu Sub SungDepartment of Radiology, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.
Hyun Kwon HaMedical Research Institute, Gangneung Asan Hospital Gangneung-si, Gangwon-do, Republic of Korea.
Yoonseok ChoiMedical Research Institute, Gangneung Asan Hospital Gangneung-si, Gangwon-do, Republic of Korea.
Dong-Cheol WooAsan Institute for Life Sciences, Asan Medical Center, Songpa-gu, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0001-8202-015X
Asan Medical Center · KRGangneung Asan Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence has suggested that hydrogen sulfide (H2S) may alleviate the cellular damage associated with cerebral ischemia/reperfusion (I/R) injury. In this study, we assessed using 1H-magnetic resonance imaging/magnetic resonance spectroscopy (1H-MRI/MRS) and histologic analysis whether H2S administration prior to reperfusion has neuroprotective effects. We also evaluated for differences in the effects of H2S treatment at 2 time points. 1H-MRI/MRS data were obtained at baseline, and at 3, 9, and 24 h after ischemia from 4 groups: sham, control (I/R injury), sodium hydrosulfide (NaHS)-30 and NaHS-1 (NaHS delivery at 30 and 1 min before reperfusion, respectively). The total infarct volume and the midline shift at 24 h post-ischemia were lowest in the NaHS-1, followed by the NaHS-30 and control groups. Peri-infarct volume was significantly lower in the NaHS-1 compared to NaHS-30 and control animals. The relative apparent diffusion coefficient (ADC) in the peri-infarct region showed that the NaHS-1 group had significantly lower values compared to the NaHS-30 and control animals and that NaHS-1 rats showed significantly higher relative T2 values in the peri-infarct region compared to the controls. The relative ADC value, relative T2 value, levels of N-acetyl-L-aspartate (NAA), and the NAA, glutamate, and taurine combination score (NGT) in the ischemic core region at 24 h post-ischemia did not differ significantly between the 2 NaHS groups and the control except that the NAA and NGT values were higher in the peri-infarct region of the NaHS-1 animals at 9 h post-ischemia. In the ischemic core and peri-infarct regions, the apoptosis rate was lowest in the NaHS-1 group, followed by the NaHS-30 and control groups. Our results suggest that H2S treatment has neuroprotective effects on the peri-infarct region during the evolution of I/R injury. Furthermore, our findings indicate that the administration of H2S immediately prior to reperfusion produces the highest neuroprotective effects.

Indexed as

AnimalsApoptosisAspartic AcidBrain IschemiaDisease Models, AnimalGlutamic AcidHumansHydrogen SulfideNeuroprotective AgentsRatsReperfusion InjuryStrokeTaurineAspartic AcidGlutamic AcidHydrogen SulfideN-acetylaspartateNeuroprotective AgentsTaurine

Identifiers

PMID29161281
PMCPMC5697867
OpenAlexW2769916410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.